Full Press Release Details
BRIDGEWATER, N.J. , Aug. 21, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences:
These events will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com . Webcasts will be archived for a period of 30 days following the conclusion of the live events.
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
Contact: Investors: Bryan Dunn Vice President, Investor Relations (646) 812-4030 [email protected]
Media: Claire Mulhearn Vice President, Corporate Communications (862) 842-6819 [email protected]
SOURCE Insmed Incorporated